Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

Phase 3

Completed

• Conditions: Birch Pollen Allergy

• Registration Number: NCT00309062
• Lead Sponsor: Allergopharma GmbH & Co. KG

Brief Summary

Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis

Detailed Description

Not available

Study Timeline

• Study Start: 2003-12
• Study First Submitted: 2006-03-30
• Study First Submitted QC: 2006-03-30
• Study First Posted: 2006-03-31
• Primary Completion: 2006-06
• Study Completion: 2009-06
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-08
• Last Update Posted: 2013-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Positive Skin Prick Test reaction to birch pollen
• Positive RAST result to birch pollen
• Positive Provocation Test result to birch pollen

Exclusion Criteria

• Serious chronic diseases
• Other perennial allergies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Allergopharma GmbH & Co. KG; 🇩🇪 Reinbek, Germany